6-(三氟甲基)吡啶-2-甲酸置于氯化亚砜,乙醇,五氯化磷,Sodium,碳酸氢钠体系中,用 四氢呋喃,丙酮,三氯氧磷 用作溶剂,化学反应 25.17H,反应生成Ag221甲磺酸盐 参考文献: Crystalline Forms Of Therapeutically Active Compounds And Use Thereof[fr] Formes Cristallines De Composés Thérapeutiquement Actifs Et Utilisation Associée 标题: Crystalline Forms Of Therapeutically Active Compounds And Use Thereof[fr] Formes Cristallines De Composés Thérapeutiquement Actifs Et Utilisation Associée 摘要:提供了2-甲基-1-[(4-[6-(三氟甲基)吡啶-2-基]-6-{[2-(三氟甲基)吡啶-4-基]氨基}-1,3,5-三嗪-2-基)氨基]丙醇(Compound 3),2-甲基-1-[(4-[6-(三氟甲基)吡啶-2-基]-6-{[2-(三氟甲基)吡啶-4-基]氨基}-1,3,5-三嗪-2-基)氨基]丙醇甲磺酸盐(Compound 1)的结晶形式及其用途.
专利号:US-2022118094-A1 优先权日:2019-02-21 标题:Synthesis of biomimetic cell wall structure 发明人:WANG YONG; SHI PENG 权利人:PENN STATE RES FOUND 摘要:The present invention relates generally to methods of generating a biomimetic cell wall (BCW) on a target surface, compositions comprising the BCW, and methods of use of the compositions, including biomedical applications of the BCW coated compositions.
专利号:US-2023391824-A1 优先权日:2021-02-08 标题:Rationale, design, synthesis and validation of a small molecule anticancer agent 发明人:JAIN MOHIT; NARENDRAN ARUMUGAVADIVEL 权利人:NARENDRAN ARUMUGAVADIVEL 摘要:LIN28 is an RNA binding protein that binds and inhibits the expression and maturation of Iet7 microRNA that carries key tumor suppressor functions. Thus, LIN28 is a feasible and effective molecular target for directed inhibition with the potential to provide therapeutic benefit to a diverse group of aggressive malignancies. The present disclosure relates generally to the Rationale, Design, Synthesis and Validation of a Novel Small Molecule Inhibitor of LIN28, coined Compound of formula (I), for the Treatment of Adult and Pediatric Malignancies. In addition, indications of this agent to block cancer metastasis, inhibit cancer stem cells to prevent relapse, and to synergize with immunotherapy, chemotherapy and radiotherapy are also been described.
专利号:WO-2025137620-A1 优先权日:2023-12-21 标题:Methods for high quality and high accuracy methylation sequencing 发明人:KENNEDY ANDREW 权利人:GUARDANT HEALTH INC 摘要:Provided herein are methods and compositions for calibrating one or more base calling metrics in a sequencing by synthesis reaction, and for calling at least a portion of nucleobases in a converted region of a DNA molecule using the one or more calibrated base calling metrics. Provided herein are also methods for determining the likelihood that a subject has a disease or condition, such as cancer.
专利号:EP-4288444-A1 优先权日:2021-02-08 标题:Rationale, design, synthesis and validation of a small molecule anticancer agent
专利号:WO-2022165606-A1 优先权日:2021-02-08 标 题:Rationale, design, synthesis and validation of a small molecule anticancer agent
专利号:CA-3207354-A1 优先权日:2021-02-08 标题:Rationale, design, synthesis and validation of a small molecule anticancer agent
1: Dittakavi S, Hallur G, Purra BR, Kiran V, Zakkula A, Mullangi R. Validated LC-MS/MS Method for Simultaneous Quantitation of Enasidenib and its Active Metabolite, AGI-16903 in Small Volume Mice Plasma: Application to a Pharmacokinetic Study. Drug Res (Stuttg). 2019 Oct 25. doi: 10.1055/a-1024-3623. [Epub ahead of print] Available from http://www.ncbi.nlm.nih.gov/books/NBK548492/ doi: 10.2147/CMAR.S162784. eCollection 2019. 4: Del Principe MI, Paterno G, Palmieri R, Maurillo L, Buccisano F, Venditti A. An evaluation of enasidenib for the treatment of acute myeloid leukemia. Expert Opin Pharmacother. 2019 Nov;20(16):1935-1942. doi: 10.1080/14656566.2019.1654456. Epub 2019 Aug 27. doi: 10.1002/bmc.4658. Epub 2019 Sep 2. doi: 10.2147/CE.S172912. eCollection 2019. 7: Pollyea DA, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS, Frattini MG, Xu Q, Tosolini A, See WL, MacBeth KJ, Agresta SV, Attar EC, DiNardo CD, Stein EM. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019 Nov;33(11):2575-2584. doi: 10.1038/s41375-019-0472-2. Epub 2019 Apr 9. doi: 10.2147/CPAA.S192687. eCollection 2019.
合成参考文献
参考文献:10.1007/978-981-99-9183-9_11 摘要:Sengupta T, Khan A, Nambiar M, Nishana M. Targeting the Epigenetic Landscape for Cancer Therapy. 2024. In: Drugs from Nature: Targets, Assay Systems and Leads.